However, whole-human-genome expression arrays revealed increased MYL9 expression in pancreatic tissue in comparison with normal expression, indicating better disease- and metastasis-free survival and OS rates and demonstrating MYL9 as a novel biomarker for pancreatic ductal adenocarcinoma (PDAC) [18]. This evidence concerns the gene MYL9 and pancreatic ductal adenocarcinoma.